| Literature DB >> 31884737 |
Ma Karen Celine C Ilagan1, Elizabeth Paz-Pacheco2, Darwin Z Totesora2, Lyra Ruth Clemente-Chua3, Jundelle Romulo K Jalique4.
Abstract
BACKGROUND: The modified Ferriman-Gallwey (mFG) score is the gold standard for the clinical evaluation of hirsutism. However, racial variations in terminal hair growth limit this tool. This study aimed to determine the mFG cut-off score among Filipino women and its association with biochemical hyperandrogenism.Entities:
Keywords: Gonadal disorders; Hirsutism; Hyperandrogenism; Polycystic ovary syndrome
Mesh:
Substances:
Year: 2019 PMID: 31884737 PMCID: PMC6935772 DOI: 10.3803/EnM.2019.34.4.374
Source DB: PubMed Journal: Endocrinol Metab (Seoul) ISSN: 2093-596X
2003 Rotterdam Criteria for the Diagnosis of Polycystic Ovary Syndrome
| Rotterdam criteria (must meet 2 out of 3 of the following) | |||
|---|---|---|---|
| (1) Hyperandrogenism | (2) Oligo-ovulation or anovulation | (3) Polycystic ovaries on ultrasound | |
| Clinical and/or | Biochemical | ||
| Hirsutism (mFG score ≥8) Acne | Elevated TT or FT | Bleeding interval <21 days | Presence of 12 or more follicles 2–9 mm in diameter in either ovary and/or |
| Male-pattern alopecia | Elevated A4 | Bleeding interval >35 days <8 episodes of menses/year | Increased ovarian volume >10 mL (without a cyst or dominant follicle) in either ovary |
| mFG, modified Ferriman-Gallw droepiandrosterone sulfate. | Elevated DHEA | Infertility | |
| Elevated DHEAS | No menstruation for 3 consecutive months in the last 12 months | ||
mFG, modified Ferriman-Gallwey; TT, total testosterone; FT, free testosterone; A4, androstenedione; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate.
Clinical Characteristics of the Study Population
| Characteristic | PCOS ( | Non-PCOS ( | |
|---|---|---|---|
| Age, yr | 27.7±4.7 | 27.5±4.4 | 0.808 |
| History of hair removal | 3 (10.7) | 16 (16.0) | 0.764 |
| History of parity | 4 (14.3) | 17 (17.0) | 1.000 |
| Age of menarche, yr | 12.0±1.3 | 11.7±1.2 | 0.198 |
| Co-morbidities | |||
| Diabetes | 4 (14.3) | 0 | 0.002 |
| Hypertension | 0 | 0 | - |
| Dyslipidemia | 1 (3.6) | 1 (1.0) | 0.391 |
| Family history of polycystic ovary syndrome | 10 (35.7) | 17 (17.0) | 0.039 |
| Body mass indexa, kg/m2 | 28.5±5.9 | 23.9±4.5 | <0.001 |
| Waist-to-hip ratio | 0.9±0.1 | 0.8±0.1 | <0.001 |
| Systolic blood pressure, mm Hg | 110±11.9 | 102.6±11.8 | 0.004 |
| Diastolic blood pressure, mm Hg | 76.4±8.7 | 71.6±10.1 | 0.023 |
| Clinical hyperandrogenism | 13 (46.4) | 4 (4.0) | <0.001 |
| Acne | 9 | 0 | |
| Hirsutism | 4 | 4 | |
| Biochemical hyperandrogenism | 6 (21.4) | 0 | <0.001 |
| Oligo-ovulation or anovulation | 27 (96.4) | 0 | <0.001 |
| Polycystic ovaries on ultrasound | 26 (92.9) | 20 (20.6) | <0.001 |
Values are expressed as mean±standard deviation or number (%).
PCOS, polycystic ovary syndrome.
aBody mass index was calculated as the participant's weight in kilograms divided by the square of the participant's height in meters.
Mean Biochemical Characteristics of the Study Population
| Characteristic | PCOS ( | Non-PCOS ( | |
|---|---|---|---|
| Total testosterone, ng/mL | 0.5±0.1 | 0.3±0.1 | <0.001 |
| Sex hormone-binding globulin, nmol/L | 23.5±16.0 | 41.9±28.0 | 0.001 |
| Free androgen index | 10.4±7.6 | 3.2±2.2 | <0.001 |
| Calculated free testosterone, pmol/L | 39.8±18.2 | 16.8±8.5 | <0.001 |
| Thyroid-stimulating hormone, μIU/mL | 1.8±0.6 | 1.6±0.8 | 0.282 |
| Prolactin, ng/mL | 12.4±5.5 | 14.9±5.3 | 0.089 |
| 17-Hydroxyprogesterone, ng/mL | 1.4±0.3 | 1.4±0.4 | 0.931 |
Values are expressed as mean±standard deviation.
PCOS, polycystic ovary syndrome.
Modified Ferriman-Gallwey Score of the Study Population
| Site | PCOS ( | Non-PCOS ( | |
|---|---|---|---|
| Upper lip | 1.2±0.7 (0.9–1.4) | 0.7±0.6 (0.5–0.8) | <0.001 |
| Chin | 0.1±0.3 (0–0.2) | 0.1±0.3 (0–0.1) | 0.882 |
| Chest | 0.0±0.2 (0–0.1) | 0.0±0.2 (0–0.1) | 0.879 |
| Upper back | 0.5±0.7 (0.3–0.8) | 0.3±0.5 (0.2–0.4) | 0.029 |
| Lower back | 0.2±0.4 (0.1–0.4) | 0.1±0.3 (0–0.2) | 0.093 |
| Upper abdomen | 0.6±0.7 (0.3–0.8) | 0.2±0.4 (0.1–0.3) | 0.001 |
| Lower abdomen | 0.8±1.1 (0.4–1.2) | 0.3±0.5 (0.2–0.4) | 0.001 |
| Upper arm | 0.2±0.5 (0–0.4) | 0.1±0.3 (0–0.1) | 0.093 |
| Thighs | 0.7±1.0 (0.3–1) | 0.3±0.6 (0.2–0.4) | 0.012 |
| Total | 4.3±3.0 (3.2–5.4) | 2.0±2.2 (1.6–2.4) | <0.001 |
Values are expressed as mean±standard deviation (95% confidence interval).
PCOS, polycystic ovary syndrome.
Fig. 1Boxplots representing the distribution of total modified Ferriman-Gallwey (mFG) scores in the non-polycystic ovary syndrome (PCOS) group (A) and the PCOS group (B). The mean total mFG scores for the two groups were: non-PCOS group, 2.0±2.2; PCOS group, 4.3±3.0.
Associations of Hirsutism with Biochemical Test Results
| Variable | Total mFG ≥7 ( | Total mFG <7 ( | Adjusted odds ratioa (95% CI) | |
|---|---|---|---|---|
| Elevated TT | 1 (10.0) | 5 (4.2) | 2.248 (0.232–21.765) | 0.423 |
| Elevated FAI | 4 (40.0) | 18 (15.3) | 3.564 (0.735–17.296) | 0.115 |
| Elevated calculated FT | 4 (40.0) | 12 (10.2) | 6.209 (1.190–32.398) | 0.030 |
Values are expressed as number (%).
mFG, modified Ferriman-Gallwey; CI, confidence interval; TT, total testosterone; FAI, free androgen index; FT, free testosterone.
aAdjusted for its covariates (age and body mass index).
Comparison of Modified Ferriman-Gallwey Cut-off Scores across Various Asian Populations
| Study | Country | Population | Suggested mFG cut-off score |
|---|---|---|---|
| Karimah et al. (2016) [ | Indonesia | 30 | ≥2 |
| Li et al. (2012) [ | China | 10,120 | ≥5a |
| Kim et al. (2011) [ | Korea | 1,010 | ≥6a |
| Cheewadhanaraks et al. (2004) [ | Thailand | 531 | ≥3a |
mFG, modified Ferriman-Gallwey.
aCut-off value based on the 95th percentile of an unselected population.